ADRC News

Lifestyle and chronic health conditions in middle age, along with a person’s education level, show associations with emerging blood markers of neurodegeneration and Alzheimer's disease.

More than 50 students and faculty from the University of Wisconsin–Madison participated and presented at the 2023 Alzheimer’s Association International Conference (AAIC) in Amsterdam, Netherlands.

Nathaniel Chin, MD, joined WPR's Central Time and The Morning Show to discuss the FDA's full approval of Leqembi (lecanemab-Irmb) and dementia care.

Nathaniel Chin, MD, was quoted in an article by CNN highlighting the Phase 3 clinical trial results of donanemab, a monoclonal antibody seeking approval from the U.S. Food and Drug Administration (FDA).

Maria Mora Pinzon, MD, MS, spoke to Telemundo Wisconsin about the approval of the Alzheimer’s disease treatment Leqembi (lecanemab-Irmb).

Maria Mora Pinzon, MD, MS, FACPM, and Beth Fields, PhD, OTR/L, BCG, have been named 2023 Faculty Scholars with the National Institute on Aging (NIA) IMPACT Collaboratory.

The council focuses on emerging issues and supports the development of resources and programs for psychiatric education across the United States.

Cynthia Carlsson, MD, MS, spoke to multiple media outlets after the U.S. Food and Drug Administration’s (FDA) full approval of lecanemab was announced. She emphasized the treatment will only be approved for people who are diagnosed with mild cognitive impairment (MCI) or mild dementia and also meet other limited criteria.

On July 6, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb), a therapy for Alzheimer’s disease shown to slow the cognitive decline associated with the disease.

The renewal grant will enable continued in-depth study into biological indicators of Alzheimer’s disease, expansion of the project to identify other causes of cognitive decline, and enhance the diversity of the cohort through recruitment of people from communities historically underrepresented in research.